News | Point-of-Care Ultrasound (POCUS) | January 08, 2024

Butterfly iQ3 brings unparalleled image quality and new digital imaging modes, iQ Slice and iQ Fan, powered by advanced semiconductor technology for easier, automated image acquisition

Butterfly iQ3 will feature a brand-new ergonomic design, to be revealed soon. (Graphic: Business Wire)

Butterfly iQ3 will feature a brand-new ergonomic design, to be revealed soon. (Graphic: Business Wire)


January 8, 2024 — Butterfly Network, Inc., a digital health company transforming care through the power of portable, semiconductor-based ultrasound technology and intuitive software, today announced the FDA clearance of its next-generation handheld point-of-care ultrasound (POCUS) system, Butterfly iQ3. The new device is the company’s third iteration of the world’s first semiconductor-based single-probe, whole-body ultrasound system. Butterfly iQ3 features a brand-new ergonomic design and will deliver double the data processing speed for optimized image resolution, sensitivity and penetration, as well as faster 3D capabilities to power novel, automated image capture modes: iQ Slice and iQ Fan.

“Butterfly iQ3 is the turning point for digital ultrasound. Butterfly started a revolution in ultrasound when we commercialized the world’s first fully digital handheld ultrasound in 2018, and subsequently, iQ+ in 2020,” said Joseph DeVivo, Butterfly Network’s President, Chief Executive Officer and Chairman. “Over 145,000 customers have since realized the value of our chip-based ultrasound. With iQ3, the revolution takes full charge. Physicians across disciplines now rank our overall image quality at least equal to traditional piezoelectric-based handhelds, and our new digital capabilities are designed to make ultrasound more accessible and approachable than ever before.”

DeVivo continued, “I look forward to revealing more about iQ3’s advanced imaging capabilities this week at the 42nd Annual J.P. Morgan Healthcare Conference. Stay tuned for more details about the product and its commercial launch in the United States this quarter.”

DeVivo and Heather Getz, Butterfly Network’s Chief Financial and Operations Officer, will present at the J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 9:00 am PT. Access the live webcast via the Events & Presentations section of Butterfly’s investor website.

For more information: https://www.butterflynetwork.com/


Related Content

News | Cardiac Imaging

Oct. 24, 2025 —YorLabs, Inc., a medical technology company developing next-generation intracardiac imaging solutions for ...

Time October 27, 2025
arrow
News | Endoscopes

Oct. 22, 2025 — Fujifilm Healthcare Americas Corp. has launched its advanced endoscopy platform, the ELUXEO 8000 ...

Time October 23, 2025
arrow
News | X-Ray

Oct. 22, 2025 — Imaging technology company Adaptix has begun live imaging trials as part of a research program at the ...

Time October 22, 2025
arrow
News | Computed Tomography (CT)

Oct. 9, 2025 — Harrison.ai has received three FDA Breakthrough Device Designations for CT imaging solutions, further ...

Time October 21, 2025
arrow
News | Contrast Media

Oct. 21, 2025 — Subtle Medical, Inc., a provider of AI-powered medical imaging solutions, has announced positive ...

Time October 21, 2025
arrow
News | Artificial Intelligence

Oct. 20, 2025 — Viz.ai has launched of Viz Assist, a suite of autonomous AI agents that significantly enhance how care ...

Time October 20, 2025
arrow
News | Point-of-Care Ultrasound (POCUS)

Oct. 15, 2025 — GE HealthCare has announced the latest advancement in its Venue family of point-of-care ultrasound ...

Time October 16, 2025
arrow
News | Women's Health

Oct. 3, 2025 — IceCure Medical Ltd., developer of minimally-invasive cryoablation technology that destroys tumors by ...

Time October 06, 2025
arrow
News | Magnetic Resonance Imaging (MRI)

September 24, 2025—According to the American Journal of Roentgenology (AJR), MRI can reliably identify lateral meniscal ...

Time October 03, 2025
arrow
News | Radiopharmaceuticals and Tracers

Oct. 01, 2025 – Nuclidium AG, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time October 02, 2025
arrow
Subscribe Now